Detalhe da pesquisa
1.
Multiple sclerosis.
Lancet
; 403(10422): 183-202, 2024 Jan 13.
Artigo
em Inglês
| MEDLINE | ID: mdl-37949093
2.
Cognitive phenotypes predict response to restorative cognitive rehabilitation in multiple sclerosis.
Mult Scler
; 30(3): 448-452, 2024 Mar.
Artigo
em Inglês
| MEDLINE | ID: mdl-37942544
3.
Paramagnetic rim lesions are associated with greater incidence of relapse and worse cognitive recovery following relapse.
Mult Scler
; 29(8): 1033-1038, 2023 07.
Artigo
em Inglês
| MEDLINE | ID: mdl-37161349
4.
Predicting employment deterioration with the Processing Speed Test (PST) and SDMT in multiple sclerosis.
Mult Scler
; 29(10): 1327-1336, 2023 09.
Artigo
em Inglês
| MEDLINE | ID: mdl-37503838
5.
Auditory Test of Processing Speed: Preliminary validation of a smartphone-based test of mental speed.
Mult Scler
; 29(13): 1646-1658, 2023 Nov.
Artigo
em Inglês
| MEDLINE | ID: mdl-37842763
6.
Benchmarks of meaningful improvement on neurocognitive tests in multiple sclerosis.
Mult Scler
; 28(3): 487-491, 2022 Mar.
Artigo
em Inglês
| MEDLINE | ID: mdl-34498512
7.
Interpreting change on the Symbol Digit Modalities Test in people with relapsing multiple sclerosis using the reliable change methodology.
Mult Scler
; 28(7): 1101-1111, 2022 06.
Artigo
em Inglês
| MEDLINE | ID: mdl-34612114
8.
Staging and stratifying cognitive dysfunction in multiple sclerosis.
Mult Scler
; 28(3): 463-471, 2022 Mar.
Artigo
em Inglês
| MEDLINE | ID: mdl-33951975
9.
Long-term efficacy and safety of siponimod in patients with secondary progressive multiple sclerosis: Analysis of EXPAND core and extension data up to >5 years.
Mult Scler
; 28(10): 1591-1605, 2022 09.
Artigo
em Inglês
| MEDLINE | ID: mdl-35380078
10.
Effect of siponimod on magnetic resonance imaging measures of neurodegeneration and myelination in secondary progressive multiple sclerosis: Gray matter atrophy and magnetization transfer ratio analyses from the EXPAND phase 3 trial.
Mult Scler
; 28(10): 1526-1540, 2022 09.
Artigo
em Inglês
| MEDLINE | ID: mdl-35261318
11.
Do subcortical gray matter volumes and aerobic capacity account for cognitive-motor coupling in multiple sclerosis?
Mult Scler
; 27(3): 401-409, 2021 03.
Artigo
em Inglês
| MEDLINE | ID: mdl-32228278
12.
Conscientiousness and deterioration in employment status in multiple sclerosis over 3 years.
Mult Scler
; 27(7): 1125-1135, 2021 06.
Artigo
em Inglês
| MEDLINE | ID: mdl-32757907
13.
A validation study for remote testing of cognitive function in multiple sclerosis.
Mult Scler
; 27(5): 795-798, 2021 04.
Artigo
em Inglês
| MEDLINE | ID: mdl-32662747
14.
Quantifying cognition and fatigue to enhance the sensitivity of the EDSS during relapses.
Mult Scler
; 27(7): 1077-1087, 2021 06.
Artigo
em Inglês
| MEDLINE | ID: mdl-33259273
15.
Recovery of cognitive function after relapse in multiple sclerosis.
Mult Scler
; 27(1): 71-78, 2021 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-31971066
16.
Lower total cerebral arterial flow contributes to cognitive performance in multiple sclerosis patients.
Mult Scler
; 26(2): 201-209, 2020 02.
Artigo
em Inglês
| MEDLINE | ID: mdl-30625030
17.
Trait Conscientiousness predicts rate of longitudinal SDMT decline in multiple sclerosis.
Mult Scler
; 26(2): 245-252, 2020 02.
Artigo
em Inglês
| MEDLINE | ID: mdl-30615562
18.
Dalfampridine benefits ambulation but not cognition in multiple sclerosis.
Mult Scler
; 26(1): 91-98, 2020 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-30566030
19.
Serum neurofilament light chain level associations with clinical and cognitive performance in multiple sclerosis: A longitudinal retrospective 5-year study.
Mult Scler
; 26(13): 1670-1681, 2020 11.
Artigo
em Inglês
| MEDLINE | ID: mdl-31610732
20.
Trait Conscientiousness predicts rate of brain atrophy in multiple sclerosis.
Mult Scler
; 26(11): 1433-1436, 2020 10.
Artigo
em Inglês
| MEDLINE | ID: mdl-31219390